Zena Quezado

Dr. Zena Quezado


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
NDNancy Diazgranados
Nancy Diazgranados
LILobna Ibrahim
Lobna Ibrahim
NBNancy E. Brutsche
Nancy E. Brutsche
ANAndrew Newberg
Andrew Newberg
PKPhillip Kronstein
Phillip Kronstein
CZCarlos A. Zarate
Carlos A. Zarate
Bipolar disorder (BPD) is one of the most severe psychiatric disorders and ranks in the top 10 causes of medical disability worldwide. The lifetime prevalence is approximately 4% in the United States,1 with depressive symptomatology dominating the longitudinal course of the illness.2 Currently approved treatments for bipolar depression include lithium, quetiapine, and the combination olanzapine and fluoxetine. Other treatments used during the depressive phase of the illness include lamotrigine, antidepressants, and atypical antipsychotics. However, many patients with bipolar depression do not respond adequately to these medications despite adequate trials.2-4 Another limitation of existing therapeutics is that they are associated with a considerable lag of onset; only a fraction of patients meet response criteria by the end of the first week of treatment.5-7 This delayed onset of antidepressant effects can result in considerable morbidity, including increased suicide risk.8,9 Therefore, rapid-onset pharmacological strategies with pronounced and sustained effects would have an enormous impact on public health; this is particularly true because BPD is perhaps the psychiatric disorder with the highest mortality rate.10

3 June 2021 in Blood
Verified
Journal Article
Open access
PDF file
LTLaxminath Tumburu
Laxminath Tumburu
SGShohini Ghosh-Choudhary
Shohini Ghosh-Choudhary
FSFayaz Seifuddin
Fayaz Seifuddin
EBEmilia A. Barbu
Emilia A. Barbu
SYSimon Yang
Simon Yang
STSwee Lay Thein
Swee Lay Thein
The pathophysiology of sickle cell disease (SCD) is driven by chronic inflammation fueled by damage associated molecular patterns (DAMPs). We show that elevated cell-free DNA (cfDNA) in patients with SCD is not just a prognostic biomarker, it also contributes to the pathological inflammation. Within the elevated cfDNA, patients with SCD had a significantly higher ratio of cell-free mitochondrial DNA (cf-mtDNA)/cell-free nuclear DNA compared with healthy controls. Additionally, mitochondrial DNA in patient samples showed significantly disproportionately increased hypomethylation compared with healthy controls, and it was increased further in crises compared with steady-state. Using flow cytometry, structured illumination microscopy, and electron microscopy, we showed that circulating SCD red blood cells abnormally retained their mitochondria and, thus, are likely to be the source of the elevated cf-mtDNA in patients with SCD. Patient plasma containing high levels of cf-mtDNA triggered the formation of neutrophil extracellular traps (NETs) that was substantially reduced by inhibition of TANK-binding kinase 1, implicating activation of the cGAS-STING pathway. cf-mtDNA is an erythrocytic DAMP, highlighting an underappreciated role for mitochondria in sickle pathology. These trials were registered at www.clinicaltrials.gov as #NCT00081523, #NCT03049475, and #NCT00047996.

1 June 2010 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
MGMeral Gunay-Aygun
Meral Gunay-Aygun
EFEsperanza Font-Montgomery
Esperanza Font-Montgomery
LLLinda Lukose
Linda Lukose
MTMaya Tuchman
Maya Tuchman
JGJennifer Graf
Jennifer Graf
WGWilliam A. Gahl
William A. Gahl
Background and objectives: Renal function and imaging findings have not been comprehensively and prospectively characterized in a broad age range of patients with molecularly confirmed autosomal recessive polycystic kidney disease (ARPKD). Design, setting, participants, & measurements: Ninety potential ARPKD patients were examined at the National Institutes of Health Clinical Center. Seventy-three fulfilled clinical diagnostic criteria, had at least one PKHD1 mutation, and were prospectively evaluated using magnetic resonance imaging (MRI), high-resolution ultrasonography (HR-USG), and measures of glomerular and tubular function. Results: Among 31 perinatally symptomatic patients, 25% required renal replacement therapy by age 11 years; among 42 patients who became symptomatic beyond 1 month (nonperinatal), 25% required kidney transplantation by age 32 years. Creatinine clearance (CrCl) for nonperinatal patients (103 ± 54 ml/min/1.73 m2) was greater than for perinatal patients (62 ± 33) (P = 0.002). Corticomedullary involvement on HR-USG was associated with a significantly worse mean CrCl (61 ± 32) in comparison with medullary involvement only (131 ± 46) (P < 0.0001). Among children with enlarged kidneys, volume correlated inversely with function, although with wide variability. Severity of PKHD1 mutations did not determine kidney size or function. In 35% of patients with medullary-only abnormalities, standard ultrasound was normal and the pathology was detectable with HR-USG. Conclusions: In ARPKD, perinatal presentation and corticomedullary involvement are associated with faster progression of kidney disease. Mild ARPKD is best detected by HR-USG. Considerable variability occurs that is not explained by the type of PKHD1 mutation.

1 July 2007 in Journal of Neurosurgery
Verified
Journal Article
Closed access
RLRussell R. Lonser
Russell R. Lonser
KWKatherine E. Warren
Katherine E. Warren
JBJohn A. Butman
John A. Butman
ZQZena Quezado
Zena Quezado
RRR. Aaron Robison
R. Aaron Robison
EOEdward H. Oldfield
Edward H. Oldfield
✓Recent preclinical studies have demonstrated that convection-enhanced delivery (CED) can be used to perfuse the brain and brainstem with therapeutic agents while simultaneously tracking their distribution using coinfusion of a surrogate magnetic resonance (MR) imaging tracer. The authors describe a technique for the successful clinical application of this drug delivery and monitoring paradigm to the brainstem. Two patients with progressive intrinsic brainstem lesions (one with Type 2 Gaucher disease and one with a diffuse pontine glioma) were treated with CED of putative therapeutic agents mixed with Gd–diethylenetriamene pentaacetic acid (DTPA). Both patients underwent frameless stereotactic placement of MR imaging–compatible outer guide–inner infusion cannulae. Using intraoperative MR imaging, accurate cannula placement was confirmed and real-time imaging during infusion clearly demonstrated progressive filling of the targeted region with the drug and Gd-DTPA infusate. Neither patient had clinical or imaging evidence of short- or long-term infusate-related toxicity. Using this technique, CED can be used to safely perfuse targeted regions of diseased brainstem with therapeutic agents. Coinfused imaging surrogate tracers can be used to monitor and control the distribution of therapeutic agents in vivo. Patients with a variety of intrinsic brainstem and other central nervous system disorders may benefit from a similar treatment paradigm.

1 October 2006 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
OVOlavo M. Vasconcelos
Olavo M. Vasconcelos
EPErika H. Poehm
Erika H. Poehm
RMRobert J. McCarter
Robert J. McCarter
WCWilliam W. Campbell
William W. Campbell
ZQZena Quezado
Zena Quezado

1 June 2007 in The Journal of Pain
Verified
Journal Article
Closed access
JFJulia Finkel
Julia Finkel
SPSophie R. Pestieau
Sophie R. Pestieau
ZQZena Quezado
Zena Quezado